DEF: Akari Seeks Shareholder Approval for Warrants, Capital Restructure

Akari Therapeutics calls a General Meeting to approve warrant exercisability and a comprehensive capital restructuring, including a share sub-division and new share allotment authority.

Summary

• Shareholders are asked to approve the exercisability of Private Placement Warrants (6,375,000 ADSs, representing 12,750,000,000 ordinary shares) issued in an October 14, 2025 offering, as required by Nasdaq Listing Rule 5635(d).
• If the Warrant Exercise Proposal is approved and warrants are exercised for cash in full, the company could receive approximately $6.25 million in gross proceeds.
• A series of interdependent resolutions (2-6) propose a capital restructuring:
• Sub-division of each ordinary share of USD 0.0001 into one new ordinary share of USD 0.000005 and 19,999 deferred shares of USD 0.000005 each.
• Granting directors general authority to allot shares up to an aggregate nominal amount of USD 3,000 (equivalent to 600,000,000,000 new ordinary shares or 300,000,000 ADSs) until June 30, 2030.
• Approval of a share buyback contract to purchase and cancel all effectively worthless Deferred Shares for an aggregate consideration of USD 0.01.
• Disapplication of statutory pre-emption rights for cash allotments until June 30, 2030, to enable more efficient fundraising.
• Adoption of New Articles of Association to reflect these changes and particularize the rights of Deferred Shares.
• The Board of Directors unanimously recommends voting FOR all proposals, stating they are in the best interests of the company and its shareholders.

Sentiment

Score: 7

Explanation: The filing outlines proactive measures to enhance capital raising flexibility and secure future funding, which are crucial for a pre-revenue biotech. The unanimous board recommendation and clear strategic rationale for aligning with US market practices are positive. However, the inherent dilution from warrant exercises and the potential market impact of future share sales introduce a degree of caution.

Positives

• Potential to realize approximately $6.25 million in gross proceeds from the full cash exercise of Private Placement Warrants.
• Enhanced flexibility in capital raising activities by reducing the nominal value of ordinary shares.
• Ability to raise funds more efficiently and in a timely fashion by granting directors authority to allot shares and disapplying pre-emption rights.
• Simplification of the capital structure through the proposed buyback and cancellation of effectively worthless Deferred Shares.
• Unanimous recommendation from the Board of Directors for all proposals, indicating strong internal alignment and belief in their strategic benefit.

Negatives

• Existing shareholders will experience dilution in their ownership interests if the Private Placement Warrants are fully exercised, leading to an aggregate of 6,375,000 ADSs (12,750,000,000 ordinary shares) becoming outstanding.
• The sale of shares underlying the Private Placement Warrants into the public market could materially and adversely affect the market price of the company's ADSs.
• Failure to approve the Warrant Exercise Proposal would prevent the exercise of warrants and could lead to substantial additional costs and expenses for the company due to required repeated shareholder meetings.
• Resolutions 2 through 6 are interdependent and conditional; failure to approve any one means none will take effect, potentially hindering the company's capital management strategy.

Risks

• Failure to obtain shareholder approval for the Warrant Exercise Proposal will mean the company cannot permit the exercise of the Private Placement Warrants and may incur substantial additional costs and expenses for holding repeated special meetings.
• Existing shareholders will suffer dilution in their ownership interests in the future to the extent that the company issues shares underlying the Private Placement Warrants.
• The sale into the public market of shares underlying the Private Placement Warrants could materially and adversely affect the market price of the company's ADSs.
• Failure to secure additional fundraisings when necessary may delay research and development activities.
• The company may be at a competitive disadvantage compared to U.S.-incorporated peer companies listed on Nasdaq if it cannot allot shares or dis-apply pre-emption rights as efficiently.

Future Outlook

The company intends to use net proceeds from the recent offering and potential warrant exercises for working capital, general corporate purposes, and continued research and development. It plans to seek additional fundraisings when necessary to implement its operating plan, believing equity financings are an appropriate method to support any potential future funding requirements for a pre-revenue-generating company.

Management Comments

• "Our directors consider that each Resolution is in the best interests of the Company and its shareholders as a whole and is likely to promote the success of the Company."
• "Accordingly, our directors unanimously recommend that you vote in favor of the Resolutions as each of the directors with personal holdings of equity interests in the Company intends to do in respect of their own beneficial holdings."
• "The Akari Board of Directors has determined and believes that each of the Resolutions outlined above is advisable to, and in the best interests of, Akari and its shareholders and has approved each such Resolution."
• "The Akari Board of Directors recommends that Akari shareholders vote FOR each such Resolution."
• "The Board believes that, in the event of an equity financing, having authorization to allot, or grant rights to subscribe for or convert securities into, our shares without needing to seek approval from shareholders under English law at the time should allow us to raise funds more efficiently on the best terms available and in a timely fashion."

Industry Context

As a pre-revenue-generating biotechnology company, Akari Therapeutics relies on equity financings to fund its operating plan and research and development. The proposed capital restructuring, particularly the disapplication of pre-emption rights, aims to align its fundraising capabilities with U.S.-incorporated peers listed on Nasdaq, who typically face fewer restrictions on share issuance. This strategic move is intended to address a potential competitive disadvantage and enable more efficient and timely capital-raising activities.

Comparison to Industry Standards

• Equivalent United States incorporated companies listed on Nasdaq are not required to seek authorization from shareholders to allot shares or to offer such shares to existing shareholders on a pre-emptive basis in the event they are pursuing an equity fundraising.
• Many of Akari's strategic competitors are incorporated in the United States where they are not subject to restrictions on their ability to issue shares.
• The requirement to first offer shares that we propose to issue for cash to all of our existing shareholders in time-consuming pro-rata rights offerings would add expense and considerably reduce the speed at which we could complete capital-raising activities undertaken in furtherance of our growth strategy and would potentially make it difficult for us to complete such transactions.

Corporate Governance

Related Party Transactions

• The company proposes to allot and issue 10 new ordinary shares to Abizer Gaslightwala (President and Chief Executive Officer) at a price of USD 0.01 per ordinary share, with part of the proceeds funding the purchase of the Deferred Shares for an aggregate price of USD 0.01.
• Directors with personal holdings of equity interests in the company intend to vote in favor of the resolutions in respect of their own beneficial holdings.

Stakeholder Impact

• Shareholders: Will experience dilution of ownership interests if Private Placement Warrants are fully exercised and from future equity raises. The capital restructuring aims to enhance the company's ability to raise capital, potentially supporting long-term growth. The nominal value change and creation of deferred shares will not directly affect the value of existing ordinary shares or ADSs but will alter the capital structure.
• Warrant Holders: Upon approval, their Private Placement Warrants will become exercisable, allowing them to convert into ADSs.
• Company Operations: The potential proceeds from warrant exercises and increased flexibility for future fundraisings are intended to support working capital, general corporate purposes, and continued research and development, which could accelerate pipeline progress.
• Management: The proposed changes grant management greater flexibility in capital management and fundraising, aligning with strategic objectives.

Next Steps

• Shareholders are encouraged to vote on the resolutions by proxy by December 11, 2025 (ordinary shareholders) or December 4, 2025 (ADS holders).
• The General Meeting of Shareholders will be held on December 15, 2025, to consider and vote on the proposed resolutions.
• If the Warrant Exercise Proposal is approved, the Private Placement Warrants will become exercisable.
• If Resolutions 2-6 are approved, the capital restructuring, including share subdivision, new allotment authority, buyback of deferred shares, and adoption of new articles, will take effect.
• The company has agreed to file a registration statement registering for resale the ADSs issuable upon exercise of the Investor Warrants and Placement Agent Warrants within 30 days of the October 16, 2025 closing date.
• If the Warrant Exercise Proposal is not approved, the company will be required to hold one or more additional special meetings of shareholders every 40 days thereafter until approval is obtained or the Investor Warrants are no longer outstanding.
• Voting results will be announced by filing a current report on Form 8-K with the SEC within four business days following the meeting.

Key Dates

Recommendation

The proposals are largely procedural and aimed at improving the company's financial flexibility and aligning its corporate governance with common practices for Nasdaq-listed entities. While the potential for future dilution exists from warrant exercises and subsequent capital raises, these steps are presented as necessary for a pre-revenue biotech to fund its operations and R&D. The board's unanimous recommendation suggests internal confidence in these strategic adjustments. Investors should hold to observe the execution of the company's operating plan and the impact of these changes on future fundraising and R&D progress.

Keywords

Akari Therapeutics, Proxy Statement, Shareholder Meeting, Warrants, Capital Restructuring, Share Subdivision, Pre-emption Rights, Nasdaq Listing Rule 5635(d), Equity Financing, Corporate Governance, Dilution, ADS, Biotechnology